# Exosomes Sector

Canonical URL: https://biopharmsignal.com/sector/exosomes

Exosomes includes companies exploring extracellular vesicles as a therapeutic delivery or regenerative medicine platform. It is still an emerging category, but it attracts attention because of its potential use in targeted delivery, tissue repair, and cell-free biologic approaches.

Companies currently grouped under Exosomes: 1

## Recent Sector News

- 2026-06-26 14:02 EST — CAPR — [Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/capricor-therapeutics-announces-fda-advisory-committee-meeting-to-review-bla-for-4de22ae1) — Source: Capricor Therapeutics
- 2026-06-26 13:05 EST — CAPR — [Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference](https://biopharmsignal.com/news/CAPR/capricor-to-present-positive-five-year-hope-2-ole-data-and-hope-3-phase-3-result-4fe04208) — Source: Capricor Therapeutics
- 2026-06-25 13:46 EST — CAPR — [Capricor Therapeutics to Present at Upcoming Investor Conferences](https://biopharmsignal.com/news/CAPR/capricor-therapeutics-to-present-at-upcoming-investor-conferences) — Source: Capricor Therapeutics
- 2026-06-25 13:46 EST — CAPR — [Capricor Therapeutics Expands Commercial Leadership Team](https://biopharmsignal.com/news/CAPR/capricor-therapeutics-expands-commercial-leadership-team) — Source: Capricor Therapeutics
- 2026-06-25 13:46 EST — CAPR — [Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/CAPR/capricor-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: Capricor Therapeutics
- 2026-06-25 13:46 EST — CAPR — [Capricor Therapeutics Takes Legal Action to Protect Patient Access to Deramiocel for Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/capricor-therapeutics-takes-legal-action-to-protect-patient-access-to-deramiocel-for-duchenne-muscular-dystrophy) — Source: Capricor Therapeutics
- 2026-06-25 13:46 EST — CAPR — [Capricor Therapeutics Announces Pricing of $150 Million Public Offering of Common Stock](https://biopharmsignal.com/news/CAPR/capricor-therapeutics-announces-pricing-of-150-million-public-offering-of-common-stock) — Source: Capricor Therapeutics
- 2026-06-25 13:46 EST — CAPR — [Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/capricor-therapeutics-and-parent-project-muscular-dystrophy-to-host-webinar-highlighting-positive-phase-3-hope-3-topline-results-in-duchenne-muscular-dystrophy) — Source: Capricor Therapeutics
- 2026-06-25 13:46 EST — CAPR — [Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data](https://biopharmsignal.com/news/CAPR/capricor-therapeutics-provides-regulatory-update-on-deramiocel-bla-following-fda-review-of-hope-3-topline-data) — Source: Capricor Therapeutics
- 2026-06-25 13:46 EST — CAPR — [Capricor Therapeutics Announces Late-Breaking Presentation at 2026 MDA Clinical and Scientific Conference](https://biopharmsignal.com/news/CAPR/capricor-therapeutics-announces-late-breaking-presentation-at-2026-mda-clinical-and-scientific-conference) — Source: Capricor Therapeutics
- 2026-06-25 13:46 EST — CAPR — [Capricor Therapeutics to Present Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Update on March 12](https://biopharmsignal.com/news/CAPR/capricor-therapeutics-to-present-fourth-quarter-and-full-year-2025-financial-results-and-recent-corporate-update-on-march-12) — Source: Capricor Therapeutics
- 2026-06-25 13:46 EST — CAPR — [Capricor Therapeutics Announces Establishment of New PDUFA Date for Deramiocel BLA](https://biopharmsignal.com/news/CAPR/capricor-therapeutics-announces-establishment-of-new-pdufa-date-for-deramiocel-bla) — Source: Capricor Therapeutics
- 2026-06-25 13:46 EST — CAPR — [Capricor Therapeutics Announces Late-Breaking HOPE-3 Data at the 2026 MDA Conference Demonstrating Significant Functional Benefits of Deramiocel for Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/capricor-therapeutics-announces-late-breaking-hope-3-data-at-the-2026-mda-conference-demonstrating-significant-functional-benefits-of-deramiocel-for-duchenne-muscular-dystrophy) — Source: Capricor Therapeutics
- 2026-06-25 13:46 EST — CAPR — [Capricor Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/CAPR/capricor-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-corporate-update) — Source: Capricor Therapeutics
- 2026-06-25 13:46 EST — CAPR — [Capricor Therapeutics to Report First Quarter 2026 Financial Results and Provide Recent Corporate Update on May 12](https://biopharmsignal.com/news/CAPR/capricor-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-recent-corporate-update-on-may-12) — Source: Capricor Therapeutics
- 2026-06-25 13:46 EST — CAPR — [Capricor Therapeutics Announces Late-Breaking Presentation of HOPE-3 Phase 3 Results at the American Academy of Neurology 2026 Annual Meeting](https://biopharmsignal.com/news/CAPR/capricor-therapeutics-announces-late-breaking-presentation-of-hope-3-phase-3-results-at-the-american-academy-of-neurology-2026-annual-meeting) — Source: Capricor Therapeutics

## Companies

- [CAPR](https://biopharmsignal.com/company/CAPR) — Capricor Therapeutics